Unknown PHASE2 INTERVENTIONAL 1-arm NCT03403101

The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer

A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of the Combination of S-1, Irinotecan and Oxaliplatin (SIRIOX) in Treating Patients With Advanced Inoperable or Metastatic Pancreatic Cancer

Sponsor: Fudan University

Conditions Carcinoma, Pancreatic Ductal

Interventions Irinotecan Oxaliplatin S1

Updated 9 times since 2018 Last updated: Apr 7, 2021 Started: Jul 1, 2020 Primary completion: Dec 31, 2023 Completion: Jul 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Carcinoma, Pancreatic Ductal and is currently ongoing. Fudan University leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Aug 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2
May 2021 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Unknown Status → Recruiting
Jan 2021 — May 2021 [monthly]

Unknown Status PHASE2

▶ Show 4 earlier versions

Sep 2020 — Jan 2021 [monthly]

Unknown Status PHASE2
Feb 2020 — Sep 2020 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jun 2018 — Feb 2020 [monthly]

Recruiting PHASE2
Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fudan University

Data source: Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China